Immunai

Immunology based personalized disease treatments

Analytics, Data, Drug Development
Artificial Intelligence Deep Learning Machine Learning

Business Overview

Decoding the immune system to improve health.

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.

Cutting-edge biology coupled with machine-learning to unravel the immune system. We are curating the largest proprietary data-set of multi-omic, immune-centric analyses of peripheral tissues. Our advanced analytics and data-visualization interface allows researchers to comprehensively view and interrogate data, and derive novel conclusions on the underlying mechanisms of disease. With a comprehensive view of the immune system, clinicians are better equipped to personalize and optimize treatment choices for each patient, and maximize positive outcomes. Immunai’s mission is to transform immunology by pioneering single-cell technologies coupled with the most cutting-edge AI methods.

Operating Status
Active
Founded
January 2019
Employees
33
Business model
B2B
Offering type
Software
Funding stage
Seed
Total funding
$20 Million
Sectors
Analytics, Data, Drug Development, Healthcare, Immunology, Personalized Treatment

Founders

Immunai
Luis Voloch
CTO
AI Expert
Immunai
Noam Solomon
CEO
AI Expert
Immunai
Danny Wells
Scientific Founder
Immunai
Ansuman Satpathy
Scientific Founder
Immunai
Dan Littman
Scientific Founder

Funding Rounds

New wpDataTable

Date Announced

Funding Round

Amount Raised

Investors

May 2020
Seed
$20 M

AI Technology Stack

AI employees
7
AI application
Vertical AI
AI types
Artificial Intelligence, Deep Learning, Machine Learning

Research

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

Vα24-invariant natural killer T (NKT) cells have shown potent anti-tumor properties in murine tumor models and have been linked to favorable outcomes in patients with cancer. However, low numbers of these cells in humans have hindered their clinical applications. Here we report interim results from all three patients enrolled on...
The interactions between antibodies, SARS-CoV-2 and immune cells contribute to the pathogenesis of COVID-19 and protective immunity. To understand the differences between antibody responses in mild versus severe cases of COVID-19, we analyzed the B cell responses in patients 1.5 months post SARS-CoV-2 infection. Severe and not mild infection correlated...
Immunotherapies that block inhibitory checkpoint receptors on T cells have transformed the clinical care of patients with cancer1. However, whether the T cell response to checkpoint blockade relies on reinvigoration of pre-existing tumor-infiltrating lymphocytes or on recruitment of novel T cells remains unclear2,3,4. Here we performed paired single-cell RNA and...

CONTACT

New York City
United States
180 Varick St, 6th Fl, 10014
Tel Aviv
Israel

INVESTMENT THESIS

Sign up for free

  • Save profiles to your list
  • View all funding rounds
  • Advanced sorting filter access
  • Search investment rounds
  • Search exit events

Sign up for Pro

  • Export lists (CSV, Excel) of startups and investors
  • View newly added AI startups
  • View investor emails
  • View investment funds and rounds sources
  • Advanced filters, sorting and search
  • Starting at just $15 per month